Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
STERIS plc reported fiscal 2024 fourth quarter ended March 31, 2024 results: revenue $1.5 billion, net income ($0.01) per diluted share, EPS ($0.01) per diluted share.
- Period
- fiscal 2024 fourth quarter ended March 31, 2024
- Revenue
- $1.5 billion
- Net income
- ($0.01) per diluted share
- EPS
- ($0.01) per diluted share
- Result
- reported results
Exact text from the filing
Total revenue for the fourth quarter of fiscal 2024 increased 10% to $1.5 billion compared with $1.4 billion in the fourth quarter of fiscal 2023.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
STERIS plc reported fiscal 2024 full year ended March 31, 2024 results: revenue $5.5 billion, net income $3.81 per diluted share, EPS $3.81 per diluted share.
- Period
- fiscal 2024 full year ended March 31, 2024
- Revenue
- $5.5 billion
- Net income
- $3.81 per diluted share
- EPS
- $3.81 per diluted share
- Result
- reported results
Exact text from the filing
Total revenue for fiscal 2024 increased 12% to $5.5 billion compared with $5.0 billion in fiscal 2023.
View on SEC.gov
Restructurings & Charges
SEC 8-K Item 2.05/2.06
confidence 0.9
STERIS plc announced a restructuring with charges of approximately $100 million affecting Healthcare surgical business in Europe.
- Type
- restructuring
- Charge
- approximately $100 million
- Affected area
- Healthcare surgical business in Europe
Exact text from the filing
this plan to potentially impacted employees on May 7, 2024 and the restructuring is expected to be substantially completed by the end of fiscal 2025. The approximately $100 million of anticipated restructuring charges includes approximately $44.4 million recorded in the fiscal 2024 fourth quarter with the balance expected to be recorded in fiscal 2025. Of
View on SEC.gov